Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia
NCT06574360
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
90
Enrollment
OTHER
Sponsor class
Conditions
Schizophrenia
Interventions
DRUG:
S1RA plus NMDAE
DRUG:
S1RA plus Placebo Cap
Sponsor
China Medical University Hospital